相关实验视频

Updated: Jun 17, 2026

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

智力障碍和痴呆症患者群体认知刺激疗法:可行性随机对照试验

Afia Ali¹, Cheryl Francis², Sarah Hoare²

¹Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

|July 31, 2025

概括

对智力障碍和痴呆症患者进行群体认知刺激疗法 (CST) 试验面临挑战. 在进行更大规模的研究之前,需要解决招聘和出席问题.

科学领域:

老年学是一门学科.
智力障碍研究智力障碍研究
临床试验可行性临床试验可行性

背景情况:

群体认知刺激疗法 (CST) 对痴呆症患者有好处,但对智力障碍 (ID) 患者的研究有限.
这项研究评估了一项随机对照试验 (RCT) 在该人群中对组CST的可行性.

研究的目的:

评估一组CST的RCT的招聘和保留可行性.
评估结果措施的适当性和CST交付可行性 (遵守性,忠实性,可接受性).
确定收集数据用于经济评估的可行性.

主要方法:

一个随机对照试验 (RCT) 在英格兰的六个NHS信托中进行.
参与者被随机分配到CST组加通常治疗 (TAU) 或单独TAU组.
测量了认知,生活质量,抑郁和服务使用;定性访谈探索了障碍和促进者.

主要成果:

34名参与者被随机分配 (18名参加CST,16名参加TAU),所有参与者都完成了随访.
结果测量的充分完成率得到了实现;CST会议的75.7%被交付.
观察到适度的忠诚度;CST是可以接受的,但障碍包括旅行和护理人员的可用性.

结论:

确定了重大挑战,包括招聘困难和随机化前学.
实际问题影响了出席率和会议的交付.
应对这些挑战对于未来对这一群体进行大规模试验至关重要.

关键词:

认知刺激疗法是一种认知刺激疗法.痴呆症痴呆症是一种痴呆症.的可行性和可行性.智力障碍智力障碍是一种智力障碍.随机对照试验是一种随机对照试验.

更多相关视频

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...